Avecho Biotechnology Ltd
ASX:AVE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.003
0.0105
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Avecho Biotechnology Ltd
ASX:AVE
|
36.7m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
5.1B EUR |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
529.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Avecho Biotechnology Ltd
Glance View
Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, and Veterinary Applications. The firm's segments include Production and Personal Care and Human Health. The Production and Personal Care segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches. The Human Health segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Avecho Biotechnology Ltd is -262.4%, which is above its 3-year median of -491.6%.
Over the last 3 years, Avecho Biotechnology Ltd’s Net Margin has decreased from -191% to -262.4%. During this period, it reached a low of -1 026.9% on Jun 30, 2024 and a high of -191% on May 30, 2022.